Sign inJoin waitlistJoin the waitlist

April Kelly Scott Salama

Associate Professor of Medicine · Duke Department of Medicine

Credentials: · ·

History

Duke Department of Medicine
Present
Duke Cancer Institute
Present

University of North Carolina at Chapel Hill School of Medicine
2004

Research

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
New England Journal of Medicine · 2015 · 2,283 citations
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,307 citations
A review of cancer immunotherapy toxicity
Review · Current Anthropology · 2020 · 1,130 citations

Georgia Beasley
25 papers
Brent Hanks
16 papers · 11 as a resident
Douglas Tyler
14 papers · 1 as a fellow
Douglas Johnson
12 papers
Omid Hamid
11 papers
Patrick Ott
10 papers
Paul Mosca
9 papers
Stephen Hodi
9 papers
Anna Pavlick
8 papers
Anthony Olszanski
8 papers
Dominick DiMaio
8 papers
Martin Fleming
8 papers

Clinical trials

IL-17 Blockade to Decrease irAEs (REPLAY)
Principal investigator · Recruiting · Phase 1
Duke University
2026–2030
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
April Salama, M.D.
2022–2027
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
Principal investigator · Completed · Phase 1
Duke University
2014–2015
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Principal investigator · Withdrawn · Phase 1
Duke University
2014–2015